- Home
- ALEC vs TCRX Comparison
ALEC vs TCRX Comparison
Compare ALEC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- TCRX
- Stock Information
- Founded
- ALEC 2013
- TCRX 2018
- Country
- ALEC United States
- TCRX United States
- Employees
- ALEC N/A
- TCRX N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ALEC Health Care
- TCRX Health Care
- Exchange
- ALEC Nasdaq
- TCRX Nasdaq
- Market Cap
- ALEC 124.0M
- TCRX 82.1M
- IPO Year
- ALEC 2019
- TCRX 2021
- Fundamental
- Price
- ALEC $1.50
- TCRX $1.47
- Analyst Decision
- ALEC Buy
- TCRX Strong Buy
- Analyst Count
- ALEC 7
- TCRX 6
- Target Price
- ALEC $4.70
- TCRX $9.50
- AVG Volume (30 Days)
- ALEC 582.2K
- TCRX 664.0K
- Earning Date
- ALEC 08-06-2025
- TCRX 08-11-2025
- Dividend Yield
- ALEC N/A
- TCRX N/A
- EPS Growth
- ALEC N/A
- TCRX N/A
- EPS
- ALEC N/A
- TCRX N/A
- Revenue
- ALEC $88,339,000.00
- TCRX $4,421,000.00
- Revenue This Year
- ALEC N/A
- TCRX $159.20
- Revenue Next Year
- ALEC $319.82
- TCRX N/A
- P/E Ratio
- ALEC N/A
- TCRX N/A
- Revenue Growth
- ALEC N/A
- TCRX N/A
- 52 Week Low
- ALEC $0.87
- TCRX $1.02
- 52 Week High
- ALEC $6.78
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- ALEC 54.62
- TCRX 47.84
- Support Level
- ALEC $1.34
- TCRX $1.39
- Resistance Level
- ALEC $1.51
- TCRX $1.73
- Average True Range (ATR)
- ALEC 0.12
- TCRX 0.13
- MACD
- ALEC -0.02
- TCRX -0.02
- Stochastic Oscillator
- ALEC 55.17
- TCRX 23.53
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.